Xeris Biopharma (XERS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Xeris Biopharma (XERS) do?
Xeris Biopharma Holdings Inc (XERS) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells prescription therapies for severe hypoglycemia, Cushing syndrome, and rare metabolic disorders. Formulates ready-to-use liquid injectable and infusible drugs that do not require reconstitution before patient use. It is worth $3.04B on the market and sold $368.06M over the last year.
- Market cap
- $3.04B
- P/E ratio
- None (reported a loss)
- Annual sales
- $368.06M
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 16, 2026
Brands and businesses behind XERS
- Gvoke: Generates revenue as a ready-to-use liquid glucagon autoinjector prescribed to treat severe low blood sugar emergencies.
- Recorlev: Earns income through prescription sales of oral cortisol synthesis inhibitor tablets for adults with Cushing syndrome.
- Keveyis: Produces revenue through prescription oral tablets used to manage episodes of primary periodic paralysis.
XERS’s flags, in plain English
Each flag is a number from Xeris Biopharma’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Wide Gross Margin
Gross margin of 84.4% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 70.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Stupid Cash
Can pay this year's bills 2.2 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Debt Is Driving
Heavy debt, 463% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about XERS
How big is Xeris Biopharma?
Xeris Biopharma’s market cap is $3.04B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $368.06M: what customers paid the company over the last year, before any costs.
What is XERS’s P/E ratio?
XERS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with XERS?
The company carries substantial long-term debt and relies on revenue from a very small portfolio of commercial drugs. That is one risk on Xeris Biopharma’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Xeris Biopharma’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. XERS’s filings on SEC.gov. The Margin Monkey is research, not advice.
